tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

PAVmed Announces Q3 2025 Financial Results and Updates

Story Highlights
  • PAVmed announced key advancements, including Veris Health’s commercial phase launch.
  • Lucid Diagnostics reported revenue growth and support for Medicare coverage of EsoGuard.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
PAVmed Announces Q3 2025 Financial Results and Updates

Meet Your ETF AI Analyst

PAVmed ( (PAVM) ) has shared an announcement.

On November 13, 2025, PAVmed Inc. announced a business update and financial results for the third quarter of 2025. The company highlighted significant advancements, including Veris Health’s commercial phase launch with The Ohio State University James Cancer Hospital and the relaunch of its implantable physiological monitor development. PAVmed also signed a letter of intent to license a new endoscopic imaging technology from Duke University, aiming to expand its innovation pipeline. Lucid Diagnostics reported $1.2 million in revenue from EsoGuard tests and received unanimous support for Medicare coverage, strengthening its financial position with a public stock offering. The company reported a GAAP net loss of $6.3 million for the quarter, with cash reserves increasing to $3.1 million.

The most recent analyst rating on (PAVM) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on PAVmed stock, see the PAVM Stock Forecast page.

Spark’s Take on PAVM Stock

According to Spark, TipRanks’ AI Analyst, PAVM is a Neutral.

PAVmed’s overall stock score is primarily impacted by its poor financial performance, characterized by severe profitability and liquidity challenges. Technical analysis provides a neutral outlook, while valuation suggests potential undervaluation but is overshadowed by financial instability. The absence of earnings call and corporate events data limits further insights.

To see Spark’s full report on PAVM stock, click here.

More about PAVmed

PAVmed Inc. is a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors. It focuses on innovative solutions, with subsidiaries like Lucid Diagnostics and Veris Health, enhancing its market presence.

Average Trading Volume: 443,400

Technical Sentiment Signal: Sell

Current Market Cap: $10.31M

See more data about PAVM stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1